AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
Study NCT03792906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Description: Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
Study NCT04651062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endocuff
Description: Endocuff is a relatively new device which is intended to be attached to the end of the colonoscope.
Study NCT04651062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no endocuff
Description: colonoscopy is performed without endocuff.
Study NCT03515330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study NCT04420104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
Study NCT04420104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv analgesia
Description: iv contromal
Study NCT04420104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv analgesia
Description: iv contromal
Study NCT03388164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + RT2CK17
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Study NCT03388164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram + Placebo
Description: Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
Study NCT02210039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECM Probe
Description: Imaging of the esophagus using SECM probe and system.
Study NCT00346697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid administration
Description: LOVAZA 1 gram capsules, 4 capsules daily
Study NCT00346697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn-oil placebo
Study NCT02731235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity training
Description: high intensity training 5 days a week for 12 weeks
Study NCT02731235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prophylactic stroke medication
Description: Usual care medication for stroke prophylaxis
Study NCT02731235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prophylactic stroke medication
Description: Usual care medication for stroke prophylaxis
Study NCT02731235 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recommendations for lifestyle changes
Description: Advise on diet, alcohol, smoking and exercise
Study NCT02731235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations for lifestyle changes
Description: Advise on diet, alcohol, smoking and exercise
Study NCT04510961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin baths therapy
Description: Patients in treatment group will receive paraffin wax baths for five days per week for 12 weeks. Prepare the paraffin device and blocks of paraffin wax. Put the paraffin wax blocks inside the tank and set the thermostat 35 to 40◦C. Melting paraffin was taken from 90 to 120 minutes. Adjust the suitable temperature for each patient before immersion of patient's hand. Submerge patient's hand completely for three to four seconds then withdraw it
Study NCT04186143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed Cinetic Chain Exercises
Description: Sit to stand, mini squat, anterior lunge, step up exercises are performed as Closed Cinetic Chain Exercises.
Study NCT04186143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open Kinetic Chain Exercises
Description: Isometric quadriceps, isotonic quadriceps, hip extension and hip adduction exercises are performed as Open Kinetic Chain Exercises.
Study NCT04186143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Control Group was followed up by conservative treatment and home program for 12 weeks and they were asked to apply the home program three days in a week. Exercise brochure was handed out for home program. Quadriceps strength and harmstring stretch exercises were applied.
Study NCT04287790 — intervention group
Intervention type: BEHAVIORAL
Intervention: audit and feedback, educational meetings, and academic detailing to promote medication receipt
Description: Our implementation intervention will incorporate the following strategies: 1) Formation of an alcohol-related care working group. This voluntary working group will consist of members of the research team and volunteer health professionals from YNHH. The group with supervise and support the other intervention components. 2) We will develop medication for alcohol use disorder marketing (posters and buttons) materials and educational (pamphlet) materials and distribute these materials to health professionals. 3) Building on the existing infrastructure and collaboration, the research team will assist in revising existing alcohol-related care daily monitoring systems to support auditing and feedback on the adoption of medications for alcohol use disorder at YNHH. 4) The research team will hold educational meetings and educational outreach visits (academic detailing) when invited during regular noon conferences and team meetings.
Study NCT04287790 — intervention group
Intervention type: DRUG
Intervention: Acamprosate, naltrexone, or disulfiram
Description: Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
Study NCT01387997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
Study NCT03588585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension
Description: Tension applied to catheter and taped firmly to leg.
Study NCT03588585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NO TENSION
Description: Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
Study NCT02567578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.1 mg
Study NCT02567578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.25 mg
Study NCT02567578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH12852 0.5 mg
Study NCT02567578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01907711 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture.
Description: Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi.
Study NCT01907711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture.
Description: Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 14 milligrams per square meter (mg/m\^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 3000 milligrams per square meter per day (mg/m\^2/day) intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
Study NCT04154189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib 14 mg/m\^2 capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until the next PD (per response evaluation criteria in solid tumors \[RECIST\] 1.1 as assessed by investigator), development of unacceptable toxicity, participant request, or withdrawal of consent, whichever occurs first.
Study NCT01559857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg once daily for 12 weeks
Study NCT01559857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Placebo
Study NCT04048772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM IVF
Description: The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
Study NCT04048772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the standard of care IVF treatment at the University of Iowa.
Study NCT01940796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
Study NCT01672671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, Paclitaxel, Cisplatin
Description: Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
Study NCT03553355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared Laser Moxibustion
Description: We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
Study NCT03553355 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Infrared Laser Moxibustion
Description: The sham laser moxibustion instrument appears to be identical as the real one.
Study NCT02112071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
Study NCT03544177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR-Walking
Description: Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
Study NCT03544177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
Study NCT00342108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cross-modal sensory stimulation
Description: comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
Study NCT00528593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa
Description: Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
Study NCT03554564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOICE/Fitbit
Description: During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
Study NCT03554564 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Daily self-reported exercise adherence
Description: During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
Study NCT00746057 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA chip
Description: One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
Study NCT01492335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Report
Description: Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
Study NCT01492335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
Study NCT01052701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)
Study NCT01052701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin plus Abacavir (ABC)
Description: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours
Study NCT01174719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: volume replacement
Description: Hydroxyethylstarch up to 50mL/kg/24 hrs
Study NCT01174719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humanalbumin 5%
Description: Humanalbumin 5% up to 50 mL/kg/24 hours
Study NCT01174719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: volume replacement
Description: up 10 50mL/kg/24 hours
Study NCT02827929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
Study NCT01328067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exablate 2100
Description: MRgFUS
Study NCT01328067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myomectomy
Description: Non-Hysteroscopic Myomectomy
Study NCT04571567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.
Study NCT02207088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablet
Study NCT02207088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: tablet
Study NCT02207088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet
Study NCT01723319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBLPADD coil deep TMS
Description: 20 daily deep TMS treatment
Study NCT01723319 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: inactive treatment
Study NCT02314819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fruquintinib
Description: fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study NCT02314819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study NCT03418818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAZA
Description: 18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
Study NCT03418818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimonidazole
Description: Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
Study NCT00580307 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Septoplasty
Description: Surgical straightening of nasal septum
Study NCT00580307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty and endoscopic contact point correction
Description: Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
Study NCT04529018 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: [18F]CETO
Description: \[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
Study NCT00734539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: 6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
Study NCT00734539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses